(redirected from Hormone therapy)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Idioms, Encyclopedia, Wikipedia.
Related to Hormone therapy: hormone replacement therapy
See: treatment
References in periodicals archive ?
For women with troubling vasomotor symptoms, premature menopause, or early-onset osteoporosis, hormone therapy appears to be both safe and efficacious.
The findings indicated that the women improved sleep quality over four years when using a low-dose hormone therapy - twice the improvement of those in the placebo group.
Comparatively, 83% of men assigned abiraterone therapy survived versus 76% of men on standard hormone therapy.
Editor's Note: Past users had higher bone mineral density at the lumbar spine and hip and a trend toward higher trabecular bone scores than those who had never used hormone therapy.
The prospective studies provided information on 12,110 postmenopausal ovarian cancer cases, 55% of whom had used hormone therapy with a median duration of 6 years.
Past users showed a much smaller increase risk of bleeding, while increasing duration of hormone therapy was significantly associated with increasing risk of major and low gastrointestinal bleeding.
Women who are discontinuing hormone therapy may benefit from alternative sleep management strategies immediately following discontinuation," she suggested.
We now have a refined understanding of the benefits and risks of hormone therapy and the evidence is now mounting that a woman's age and amount of time since onset of menopause influences her health outcomes on estrogen, particularly the risk of heart disease," Dr.
Women in all age groups saw an increased risk of stroke from hormone therapy, the new analysis confirms.
The decrease was most pronounced in women who were older than 50: women who were the prime target audience for hormone therapy.
Hormone therapy may help prevent memory loss in pre- and postmenopausal women, according to new research from the University of Michigan Health System.
Department of Defense and the first of four Phase 2 studies planned for OGX- 011 in 2005, is designed to assess the safety and efficacy of OGX-011 in prostate cancer patients receiving neoadjuvant hormone therapy.

Full browser ?